Market Research Report
Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023
|Published by||MarketsandMarkets||Product code||671105|
|Published||Content info||134 Pages
Delivery time: 1-2 business days
|Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023|
|Published: August 1, 2018||Content info: 134 Pages||
The global autoinjectors market is expected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period. Growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, and technological advancements in autoinjector devices are expected to drive the growth of the autoinjectors market. However, the preference for alternative routes of drug delivery such as oral diabetic agents and epinephrine nasal sprays is expected to restrain the growth of this market to a certain extent.
Based on therapy, the global autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies. The rheumatoid arthritis segment is expected to grow at the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the high prevalence of rheumatoid arthritis across the globe.
Based on type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the benefits these autoinjectors offer, such as portability, ease of use, and a lower possibility of infection.
North America is expected to witness the highest growth from 2018 to 2023. This can be attributed to the rising prevalence of anaphylaxis, autoimmune diseases, and chronic diseases in the US and Canada; favorable reimbursement scenario; and increasing number of awareness programs in the region.
The key players in the global autoinjectors market are: Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US), Merck (US), Ypsomed (Switzerland), AstraZeneca (UK), J&J (US), Becton Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), Bayer (Germany), and Haselmeier (Switzerland).
The report analyzes the autoinjectors market and aims at estimating the market size and future growth potential of this market based on various segments such as therapy, type, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one or any combination of the below mentioned five strategies.
This report provides insights into the following pointers:
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.